193 related articles for article (PubMed ID: 33480405)
1. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation.
Sandhu RK; Islam S; Dover DC; Andrade JG; Ezekowitz J; McAlister FA; Hawkins NM; Kaul P
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):195-201. PubMed ID: 33480405
[TBL] [Abstract][Full Text] [Related]
2. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Grymonprez M; Carnoy L; Capiau A; Boussery K; Mehuys E; De Backer TL; Steurbaut S; Lahousse L
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):722-730. PubMed ID: 37791408
[TBL] [Abstract][Full Text] [Related]
3. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis.
Grymonprez M; Vanspranghe K; Capiau A; Boussery K; Steurbaut S; Lahousse L
Br J Clin Pharmacol; 2022 Jul; 88(7):3039-3051. PubMed ID: 35132677
[TBL] [Abstract][Full Text] [Related]
4. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
[TBL] [Abstract][Full Text] [Related]
5. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
[TBL] [Abstract][Full Text] [Related]
6. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P;
Eur Heart J; 2017 Jul; 38(27):2137-2149. PubMed ID: 27282612
[TBL] [Abstract][Full Text] [Related]
7. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
8. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
[TBL] [Abstract][Full Text] [Related]
9. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.
Holm J; Mannheimer B; Malmström RE; Eliasson E; Lindh JD
Eur J Clin Pharmacol; 2021 Mar; 77(3):409-419. PubMed ID: 33029651
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.
Xiong Q; Lau YC; Lip GY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):937-48. PubMed ID: 25797167
[TBL] [Abstract][Full Text] [Related]
11. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
12. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
13. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
14. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.
Wang CL; Wu VC; Chang KH; Tu HT; Kuo CF; Huang YT; Chu PH; Kuo CC; Chang SH
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):147-154. PubMed ID: 31384926
[TBL] [Abstract][Full Text] [Related]
15. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
[TBL] [Abstract][Full Text] [Related]
17. Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation.
Park S; Je NK
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):656-664. PubMed ID: 34558337
[TBL] [Abstract][Full Text] [Related]
18. Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.
Deitelzweig S; Keshishian A; Kang A; Dhamane AD; Luo X; Klem C; Rosenblatt L; Mardekian J; Jiang J; Yuce H; Lip GYH
Adv Ther; 2021 Jun; 38(6):3166-3184. PubMed ID: 33963511
[TBL] [Abstract][Full Text] [Related]
19. Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care.
Delesie M; Ballet A; Hillegeer C; Desteghe L; Dendale P; Heidbuchel H
Clin Drug Investig; 2022 Sep; 42(9):775-786. PubMed ID: 35986867
[TBL] [Abstract][Full Text] [Related]
20. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]